AUPH Aurinia Pharmaceuticals Inc

6.39
+0.03  (+0%)
Previous Close 6.36
Open 6.4
Price To Book 4.15
Market Cap 585,620,796
Shares 91,646,447
Volume 4,268
Short Ratio
Av. Daily Volume 464,983

NewsSee all news

  1. As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential
  2. Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees
  3. ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts
  4. ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
  5. Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 22, 2019. Primary endpoint not met, secondary met.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 trial initiation announced June 2018. Interim data readouts are anticipated 2H 2019.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 data due 4Q 2019.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential
  2. Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees
  3. ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts
  4. ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
  5. Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
  6. Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders
  7. Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders
  8. Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
  9. Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
  10. Aurinia: 1Q Earnings Snapshot
  11. Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights
  12. Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis
  13. Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  14. Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen
  15. Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
  16. Former MedImmune president Greenleaf tapped to lead Canadian biotech
  17. Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
  18. Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
  19. Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript